Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Turjeman, Keren ^a   Bavli, Yaelle ^a   Kizelsztein, Pablo ^a   Schilt, Yaelle ^a   Allon, Nahum ^a   Katzir, Tamar Blumenfeld ^b   Sasson, Efrat ^b   Raviv, Uri ^a   Ovadia, Haim ^c   Barenholz, Yechezkel ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Institute of Chemistry Edmond J Safra Campus Hebrew University of Jerusalem ^*  (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; HYDROCORTISONE SODIUM SUCCINATE; LIPOSOME; METHYLPREDNISOLONE SODIUM SUCCINATE; NANOCARRIER; NANOSTERICALLY STABILIZED LIPOSOME; NITROXIDE; PEPTIDE; TEMPAMINE; UNCLASSIFIED DRUG; AMINE OXIDE; ANTIINFLAMMATORY AGENT; NANOPARTICLE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHARMACOKINETICS; ANIMAL; CHEMISTRY; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; METABOLISM; NEURODEGENERATIVE DISEASES; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; LIPOSOMES; METHYLPREDNISOLONE HEMISUCCINATE; MICE; MULTIPLE SCLEROSIS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PRODRUGS; TISSUE DISTRIBUTION;

EID: 84940042314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130442     Document Type: Article

References (80)

1. Yong VW. Inflammation in neurological disorders: A help or a hindrance? The Neuroscientist. 2010; 16 (4):408-20. doi:10.1177/1073858410371379 PMID: 20817918.
2. Zlokovic BV. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics. 2008; 5(3):409-14. doi:10.1016/j.nurt.2008.05.011 PMID: 18625452.
3. Reichardt HM, Gold R, Lühder F. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert review of neurotherapeutics. 2006; 6(11):1657-70. PMID: 17144780.
4. Vosoughi R, Freedman MS. Therapy of MS. Clinical neurology and neurosurgery. 2010; 112(5):365- 85. doi:10.1016/j.clineuro.2010.03.010 PMID: 20362388.
5. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359(9313):1221-31. PMID: 11955556.
6. Floris S, Blezer E, Schreibelt G, Döpp E, van der Pol S, Schadee-Eestermans I, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis A quantitative MRI study. Brain. 2004; 127(3):616-27.
7. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006; 129(8):1953-71.
8. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000; 157(1):267-76. PMID: 10880396.
9. Avnir Y, Turjeman K, Tulchinsky D, Sigal A, Kizelsztein P, Tzemach D, et al. Fabrication Principles and Their Contribution to the Superior in Vivo Therapeutic Efficacy of Nano-Liposomes Remote Loaded with Glucocorticoids. PloS one. 2011; 6(10):e25721. doi:10.1371/journal.pone.0025721 PMID: 21998684.
10. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: A novel approach to treating autoimmune arthritis. Arthritis & Rheumatism. 2008; 58(1):119-29.
11. Kizelsztein P, Ovadia H, Garbuzenko O, Sigal A, Barenholz Y. Pegylated nanoliposomes remoteloaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. Journal of neuroimmunology. 2009; 213(1-2):20-5. doi:10.1016/j.jneuroim.2009.05.019 PMID: 19564052.
12. Ulmansky R, Turjeman K, Baru M, Katzavian G, Harel M, Sigal A, et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. Journal of Controlled Release. 2011.
13. Wasserman V, Kizelsztein P, Garbuzenko O, Kohen R, Ovadia H, Tabakman R, et al. The antioxidant tempamine: In vitro antitumor and neuroprotective effects and optimization of liposomal encapsulation and release. Langmuir. 2007; 23(4):1937-47. PMID: 17279678.
14. Brusaferri F, Candelise L. Steriods for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials. Journal of neurology. 2000; 247(6):435-42. PMID: 10929272.
15. Milligan N, Newcombe R, Compston D. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. Journal of Neurology, Neurosurgery & Psychiatry. 1987; 50(5):511-6.
16. Tischner D, Reichardt HM. Glucocorticoids in the control of neuroinflammation. Molecular and cellular endocrinology. 2007; 275(1):62-70.
17. Pozzilli C, Marinelli F, Romano S, Bagnato F. Corticosteroids treatment. Journal of the neurological sciences. 2004; 223(1):47-51. PMID: 15261560.
18. Hoven J, Hofkens W, Wauben M, Wagenaar-Hilbers J, Beijnen J, Nuijen B, et al. Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. International Journal of Pharmaceutics. 2011; 416(2):471-7. doi:10.1016/j.ijpharm.2011.03.025 PMID: 21440612.
19. Linker RA, Weller C, Lühder F, Mohr A, Schmidt J, Knauth M, et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Experimental neurology. 2008; 211(2):397-406. doi:10.1016/j.expneurol.2008.02.005 PMID: 18394606.
20. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain. 2003; 126(8):1895-904.
21. Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs & aging. 2001; 18(9):685-716.
22. Sarsero JP, Li L, Wardan H, Sitte K, Williamson R, Ioannou PA. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. The journal of gene medicine. 2003; 5(1):72- 81. PMID: 12516053.
23. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathology. 1999; 9 (1):133-46. PMID: 9989456.
24. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. Journal of the neurological sciences. 2000; 177(2):95-103. PMID: 10980305.
25. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of neurochemistry. 2002; 69(5):2064-74.
26. Ebadi M SS, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol. 1996; 48:1-19. PMID: 8830346.
27. Borlongan C, Kanning K, Poulos S, Freeman T, Cahill D, Sanberg P. Free radical damage and oxidative stress in Huntington's disease. J Fla Med Assoc. 1996; 83(5):335-41. PMID: 8666972.
28. Afzal V, Brasch RC, Nitecki DE, Wolff S. Nitroxyl spin label contrast enhancers for magnetic resonance imaging. Studies of acute toxicity and mutagenesis. Investigative radiology. 1984; 19(6):549. PMID: 6511262.
29. DeGraff WG, Krishna MC, Kaufman D, Mitchell JB. Nitroxide-mediated protection against X-ray-and neocarzinostatin-induced DNA damage. Free Radical Biology and Medicine. 1992; 13(5):479-87. PMID: 1459474.
30. Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proceedings of the National Academy of Sciences. 1992; 89(12):5537-41.
31. Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, et al. Inhibition of oxygendependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Archives of biochemistry and biophysics. 1991; 289(1):62-70. PMID: 1654848.
32. Hahn SM, Mitchell JB, Shacter E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radical Biology and Medicine. 1997; 23(6):879-84. PMID: 9378367.
33. Zamir E, Zhang R, Samuni A, Kogan M, Pe'er J. Nitroxide stable radical suppresses autoimmune uveitis in rats. Free Radical Biology and Medicine. 1999; 27(1):7-15.
34. Anderson BD, Taphouse V. Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. J Pharm Sci. 1981; 70(2):181-6. Epub 1981/02/01. PMID: 7009782.
35. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959; 234(3):466-8. Epub 1959/03/01. PMID: 13641241.
36. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, et al. Functionalization with ApoEderived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. Journal of biotechnology. 2011; 156(4):341-6.
37. Ninomiya H, Roch J-M, Sundsmo MP, Otero D, Saitoh T. Amino acid sequence RERMS represents the active domain of amyloid beta/A4 protein precursor that promotes fibroblast growth. The Journal of cell biology. 1993; 121(4):879-86. PMID: 8491779.
38. Allon N, Saxena A, Chambers C, Doctor BP. A new liposome-based gene delivery system targeting lung epithelial cells using endothelin antagonist. Journal of Controlled Release. 2012; 160(2):217-24. doi:10.1016/j.jconrel.2011.10.033 PMID: 22079949.
39. Hammersley A, Svensson S, Hanfland M, Fitch A, Hausermann D. Two-dimensional detector software: From real detector to idealised image or two-theta scan. International Journal of High Pressure Research. 1996; 14(4-6):235-48.
40. Ben-Nun T, Ginsburg A, Szekely P, Raviv U. X+: A comprehensive computationally accelerated structure analysis tool for solution X-ray scattering from supramolecular self-assemblies. Journal of Applied Crystallography. 2010; 43(6):1522-31. doi: 10.1107/S0021889810032772.
41. Székely P, Ginsburg A, Ben-Nun T, Raviv U. Solution X-ray scattering form factors of supramolecular self-assembled structures. Langmuir. 2010; 26(16):13110-29. doi:10.1021/la101433t PMID: 20695550.
42. Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties. Journal of Controlled Release. 2009; 139(1):73-80. doi:10.1016/j.jconrel.2009.05.036 PMID: 19508880.
43. Cern A, Golbraikh A, Sedykh A, Tropsha A, Barenholz Y, Goldblum A. Quantitative structure-property relationship modeling of remote liposome loading of drugs. Journal of Controlled Release. 2011.
44. Barenholz Y, Cevc G. Structure and properties of membranes. In: Baszkin A, Norde W, editors. Physical chemistry of biological surfaces: Marcel Dekker; 2000. p. 171-241.
45. Mabrey S, Sturtevant JM. High-sensitivity differential scanning calorimetry in the study of biomembranes and related model systems: Springer; 1978.
46. Barenholz Y, Bombelli C, Bonicelli MG, Profio Pd, Giansanti L, Mancini G, et al. Influence of lipid composition on the thermotropic behavior and size distribution of mixed cationic liposomes. Journal of colloid and interface science. 2011; 356(1):46-53. doi:10.1016/j.jcis.2010.11.062 PMID: 21256506.
47. Saper G, Kler S, Asor R, Oppenheim A, Raviv U, Harries D. Effect of capsid confinement on the chromatin organization of the SV40 minichromosome. Nucleic acids research. 2013; 41(3):1569-80. doi:10.1093/nar/gks1270 PMID: 23258701.
48. Barenholz Y, Wasserman V. Tempamine compositions and methods of use. Google Patents; 2002.
49. Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chemistry and physics of lipids. 2005; 135(2):117-29. PMID: 15921973.
50. Stein WD. Transport and Diffusion Across Cell Membranes: Academic Pr; 1986.
51. Barenholz Y, Cevc G. In: Physical Chemistry of Biological interfaces. Marcel Dekker, New York; 2000.
52. Barenholz Y. Liposome application: problems and prospects. Current opinion in colloid & interface science. 2001; 6(1):66-77.
53. Maier C, Rünzler D, Schindelar J, Grabner G, WaldhäuslW, Köhler G, et al. G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. Journal of cell science. 2005; 118(15):3353-61.
54. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis & Rheumatism. 1998; 41(5):761-7.
55. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. The Journal of steroid biochemistry and molecular biology. 1995; 52(2):113-33. PMID: 7873447.
56. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. Journal of neuroimmunology. 2001; 117(1):1-8.
57. Gaillard PJ, Appeldoorn C, Rip J, Dorland R, van der Pol S, Kooij G, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. Journal of Controlled Release. 2012.
58. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharmaceutical research. 1996; 13(6):861-8. PMID: 8792423.
59. Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R, et al. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis quantification of inflammation and oedema. Brain. 1996; 119(1):239-48.
60. McCombe P, Nickson I, Tabi Z, Pender M. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of Vβ8. 2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of Vβ8. 2+ cells. Journal of neuroimmunology. 1996; 70(2):93-101. PMID: 8898717.
61. Thompson A, Kennard C, Swash M, Summers B, Yuill G, Shepherd D, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989; 39 (7):969-. PMID: 2544829.
62. Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio G, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis Clinical-immunologic correlations. Neurology. 1986; 36(2):238-. PMID: 3511404.
63. Barnes M, Bateman D, Cleland P, Dick D, Walls T, Newman P, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. Journal of Neurology, Neurosurgery & Psychiatry. 1985; 48(2):157-9.
64. Miller H, Newell D, Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (ACTH). Lancet. 1961; 2(7212):1120. PMID: 14474011.
65. Kesselring J, Miller D, MacManus D, Johnson G, Milligan N, Scolding N, et al. Quantitative magnetic resonance imaging in multiple sclerosis: The effect of high dose intravenous methylprednisolone. Journal of Neurology, Neurosurgery & Psychiatry. 1989; 52(1):14-7.
66. Triarhou LC, Herndon RM. The effect of dexamethasone on L-alpha-lysophosphatidyl choline (lysolecithin)- induced demyelination of the rat spinal cord. Archives of neurology. 1986; 43(2):121. PMID: 3947247.
67. Kermode A, Thompson A, Tofts P, MacManus D, Kendall B, Kingsley D, et al. Breakdown of the bloodbrain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis Pathogenetic and clinical implications. Brain. 1990; 113(5):1477-89.
68. Gass A, Barker G, Kidd D, Thorpe J, MacManus D, Brennan A, et al. Correlation of magnetization transfer ration with clinical disability in multiple sclerosis. Annals of neurology. 1994; 36(1):62-7. PMID: 8024264.
69. Karlik S, Munoz D, St Louis J, Strejan G. Correlation between MRI and clinico-pathological manifestations in Lewis rats protected from experimental allergic encephalomyelitis by acylated synthetic peptide of myelin basic protein. Magnetic resonance imaging. 1999; 17(5):731-7. PMID: 10372527.
70. Schellenberg AE, Buist R, Yong VW, Del Bigio MR, Peeling J. Magnetic resonance imaging of blood- spinal cord barrier disruption in mice with experimental autoimmune encephalomyelitis. Magnetic Resonance in Medicine. 2007; 58(2):298-305. PMID: 17654586.
71. Juhler M, Barry DI, Offner H, Konat G, Klinken L, Paulson OB. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat. Brain research. 1984; 302(2):347-55. PMID: 6610460.
72. Cutler RW, Lorenzo AV, Barlow CF. Brain vascular permeability to I125 gamma globulin and leukocytes in allergic encephalomyelitis. Journal of Neuropathology & Experimental Neurology. 1967; 26(4):558- 71.
73. Leibowitz S, Kennedy L. Cerebral vascular permeability and cellular infiltration in experimental allergic encephalomyelitis. Immunology. 1972; 22(5):859. PMID: 5021707.
74. Barlow CF. A study of abnormal blood-brain permeability in experimental allergic encephalomyelitis. Journal of Neuropathology & Experimental Neurology. 1956; 15(2):196-207.
75. Hawkins C, Mackenzie F, Tofts P, Du Boulay E, McDonald W. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain. 1991; 114(2):801-10.
76. Troiano R, Hafstein M, Ruderman M, Dowling P, Cook S. Effect of high-dose intravenous steriod administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Annals of neurology. 1984; 15(3):257-63. PMID: 6721447.
77. Miller D, Thompson A, Morrissey S, MacManus D, Moore S, Kendall B, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. Journal of Neurology, Neurosurgery & Psychiatry. 1992; 55(6):450-3.
78. Nessler S, Boretius S, Stadelmann C, Bittner A, Merkler D, Hartung H-P, et al. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain. 2007; 130(8):2186-98.
79. Youl B, Turano G, Miller D, Towell A, MacManus D, Moore S, et al. The pathophysiology of acute optic neuritis An association of gadolinium leakage with clinical and electrophysiological deficits. Brain. 1991; 114(6):2437-50.
80. Kappos L, Gold R, Hofmann E, Keil W, Clauß R. Multiple sclerosis: diagnostic criteria and the role of contrast enhanced MRI. Contrast media in MRI Medicom Europe, Bussum. 1990:127-35.